AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 179 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.75 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,347,000 | +21.1% | 75,400 | -8.4% | 0.00% | 0.0% |
| Q4 2020 | $1,112,000 | +22.7% | 82,337 | +6.9% | 0.00% | 0.0% |
| Q3 2020 | $906,000 | -17.3% | 77,000 | +3.8% | 0.00% | 0.0% |
| Q2 2020 | $1,095,000 | -5.7% | 74,200 | -13.7% | 0.00% | 0.0% |
| Q1 2020 | $1,161,000 | -45.3% | 86,000 | -2.1% | 0.00% | -50.0% |
| Q4 2019 | $2,122,000 | +57.1% | 87,800 | +24.9% | 0.00% | +100.0% |
| Q3 2019 | $1,351,000 | +68.7% | 70,300 | +159.4% | 0.00% | 0.0% |
| Q2 2019 | $801,000 | -32.3% | 27,100 | +8.8% | 0.00% | 0.0% |
| Q1 2019 | $1,183,000 | +29.6% | 24,900 | -1.6% | 0.00% | 0.0% |
| Q4 2018 | $913,000 | -56.5% | 25,300 | -25.7% | 0.00% | -66.7% |
| Q3 2018 | $2,097,000 | -11.7% | 34,073 | -3.0% | 0.00% | 0.0% |
| Q2 2018 | $2,374,000 | +35.9% | 35,138 | +9.1% | 0.00% | +50.0% |
| Q1 2018 | $1,747,000 | +377.3% | 32,200 | +327.9% | 0.00% | +100.0% |
| Q3 2017 | $366,000 | +36.6% | 7,525 | +47.5% | 0.00% | – |
| Q2 2017 | $268,000 | +16.0% | 5,100 | 0.0% | 0.00% | – |
| Q1 2017 | $231,000 | – | 5,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |